Dabrafenib and Tipranavir Oral Solution
Determining the interaction of Dabrafenib and Tipranavir Oral Solution and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Dabrafenib may reduce the blood levels of tipranavir, which may make the medication less effective in treating HIV infection in some cases. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition worsens or you develop new infections during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.
MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.
- "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.
- "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.
- Sommadossi JP "HIV protease inhibitors: pharmacologic and metabolic distinctions." AIDS 13 (1999): s29-40
- "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.
- Liedtke MD, Lockhart SM, Rathbun RC "Anticonvulsant and antiretroviral interactions." Ann Pharmacother 38 (2004): 482-9
- "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.
- "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.
- "Product Information. Invirase (saquinavir)." Roche Laboratories, Nutley, NJ.
- "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.
- Brooks J, Daily J, Schwamm L "Protease inhibitors and anticonvulsants." AIDS Clin Care 9 (1997): 87,90
- "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.
- Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids 14 (2000): 1333-9
- Barry M, Gibbons S, Back D, Mulcahy F "Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations." Clin Pharmacokinet 32 (1997): 194-209
- Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA "Carbamazepine-indinavir interaction causes antiretroviral therapy failure." Ann Pharmacother 34 (2000): 465-70
- Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12
Generic Name: tipranavir
Brand name: Aptivus
Synonyms: Tipranavir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dabrafenib-Tirofiban
- Dabrafenib-Tirofiban Intravenous
- Dabrafenib-Tirosint
- Dabrafenib-Tirosint-Sol
- Dabrafenib-Tisagenlecleucel
- Dabrafenib-Tisagenlecleucel Intravenous
- Tipranavir Oral Solution-Dabrafenib Mesylate
- Tipranavir Oral Solution-Dacarbazine
- Tipranavir Oral Solution-Dacarbazine Intravenous, Injection
- Tipranavir Oral Solution-Daclatasvir
- Tipranavir Oral Solution-Daclatasvir Dihydrochloride
- Tipranavir Oral Solution-Daclizumab